Response to beta interferon 1b among Saudi patients with multiple sclerosis

Saudi Medical Journal

Volumn 24, Issue 1, 2003, Pages 44-48

  Kargwell, Haga ^a   Yaqub, Basim A ^a   Al Deeb, Saleh M ^a  

^a Prince Sultan Military Medical City   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; PARACETAMOL; PAROXETINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE; ARTICLE; BODY TEMPERATURE DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HOSPITAL PATIENT; HUMAN; INJECTION SITE; INSOMNIA; MALAISE; MALE; MENSTRUATION DISORDER; MOOD DISORDER; MULTIPLE SCLEROSIS; OPEN STUDY; PUBLIC HOSPITAL; RATING SCALE; RECURRENCE RISK; SAUDI ARABIA; SKIN MANIFESTATION;

ADULT; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0037224020     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kurtzke JF. Geographic distribution of multiple sclerosis. An update with special reference to Europe and Mediterranean region. Acta Neurol Scand 1980; 62: 65-80.
2. Yaqub B, Daif A. Multiple sclerosis in Saudi Arabia. Neurology 1988; 38: 621-623.
3. Prism's Study Group. Randomized double-blind placebo-controlled study of Interferon-B1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
4. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991: 114: 1057-1067.
5. Eber GG, Paty DW. Natural history studies and applications to clinical trials. In: Paty DW, Ebers GC, editors. Multiple Sclerosis. Philadelphia (PA): F.A. Davis Co; 1997. p. 192-228.
6. IFNB Multiple Sclerosis Study Group. Interferon Beta-1b is effective in relapsing-remitting multiple sclerosis 1. Clinical results of multicentre randomized double blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
7. IFNB-Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon Beta-1b in the treatment of multiple sclerosis. Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
8. Paty DW, Li DK. Interferon Beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicentre randomized double blind, placebo-controlled trial. Neurology 1993; 43: 662-667.
9. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
10. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
11. Schumacher GA, Beebe G, Kibler RF. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965; 122: 552-568.
12. Paty DW. Trial measures in multiple sclerosis: The use of magnetic resonance imaging in the evaluation of clinical trials. Neurology 1988; 38: 82-83.
13. Paty DW, Oger JT, Kastrukoft LF, Hashimoto SA, Hooge JP, Eisen KA et al. MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal bands, and CT. Neurology 1988; 38: 180-185.
14. Liu C, Blumhardt LD. Assessing relapses in treatment trials of relapsing-remitting multiple sclerosis: Can we do better? Mult Scler 1999; 5: 22-28.
15. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. IFN-Beta 1a for disease progression in relapsing-remitting multiple sclerosis. Ann Neurol 1996; 39: 285-294.
16. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of Phase III multicentre, double blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
17. Lukes SA, Crooks LE, Aminoff MJ, Kaufman L, Panitch HS, Mills C et al. Nuclear magnetic resonance imaging in multiple sclerosis. Ann Neurol 1983; 13: 592-601.
18. Kurtzke JF. Clinical manifestations of multiple sclerosis. In: Vinken PT, Bruyn GW, editors. Handbook of Clinical Neurology. Amsterdam: North Holland Publishing Company; 1970. p. 161-201.
19. McAlpine D, Lumsden CE, Acheson ED. Multiple sclerosis. A reappraisal. 2nd ed. London (UK): Churchill Livingstone Publishers; 1972. p. 83-307.
20. Kuroiwa Y, Igata A, Hahara K, Koshijima S, Tsubaki T, Toyokura Y et al. National wide survey of multiple sclerosis in Japan: Clinical analysis of 1,084 cases. Neurology 1975; 25: 845-851.
21. Kuroiwa Y, Hung TP, Landsborough D, Suhpark C, Singha IBS, Soemargo S et al. Multiple sclerosis in Asia. Neurology 1977; 27: 188-192.
22. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419-1428.
23. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: A critique. Neurology 1988; 38: 1793-1798.
24. Fillippi M, Paty DW, Kappos L, Barkhot F, Compston DAS, Thompson AJ, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995; 45: 255-260.
25. Scharrack B, Hughes RAC. Clinical scales for multiple sclerosis. J Neurol Sci 1996; 135: 1-9.
26. Francis DA, Bain P, Swan AV, Hughes RAC. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 1991; 48: 299-301.
27. Khoury ST, Guttmann CRG, Orav EJ, Hohol MJ, Ahn SS, Hsu L et al. Longitudinal MRI in multiple sclerosis: Correlation between disability and lesion burden. Neurology 1994; 44: 2120-2124.
28. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving Interferon Beta-1b for multiple sclerosis: Report of a consensus conference. Neurology 1996; 46: 12-18.
29. Munschauer FE III, Kinkel RP. Managing side effects of Interferon Beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997; 19: 883-893.
30. Rio J, Nos C, Mazo ME, Tintore M, Montalban X. Low dose steroids reduce flu-like symptoms at the initiation of IFN-Beta 1b in relapsing-remitting multiple sclerosis. Neurology 1998; 50: 1910-1912.
31. Vial T, Descotes J. Clinical Toxicity of the interferons. Drug Saf 1994; 10: 115-150.
32. Paty DW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFN B1b (the use of an assay for neutralizing antibodies NAB). Neurology 1996; 47: 865-866.
33. Compston A. Beta Interferon and multiple sclerosis: not a final solution for the problem. Br J Hosp Med 1995; 53: 547-552.